Investor Overview

Synta Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing novel pharmaceutical products for extending and enhancing the lives of patients with severe medical conditions, including cancer and chronic inflammatory disease. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All clinical candidates were invented internally by Synta scientists using our compound library and discove... More >>

Date Title   09/08/10 Synta Pharmaceuticals to Present at the Robert W. Baird 2010 Health Care Conference Company to Webcast Presentation on September 14 LEXINGTON, Mass., Sep 8, 2010 (BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA - News), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Company will be presenting at the Robert W. Baird 2010 Health Care Conference on Tuesday, September 14 at 3:45 p.m. (ET) in New York. A live audio webcast and replay of the presenta...  08/24/10 Synta Announces First Patient Treated in Clinical Trial of STA-9090 in Combination with Docetaxel in Solid Tumors First combination trial of potent second-generation Hsp90 inhibitor LEXINGTON, Mass., Aug 24, 2010 (BUSINESS WIRE) -- Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the first patient has been treated in its clinical trial of STA-9090 in combination with docetaxel for the treatment of advanced solid tumor malignancies. This is the first ...  08/09/10 Synta Pharmaceuticals Reports Second-Quarter 2010 Financial Results and Clinical Update - STA-9090 Phase 2 trials in hepatic and small cell lung cancer initiated - - First STA-9090 combination trial initiated - - Additional evidence supportive of predictive role for LDH in elesclomol activity shown - LEXINGTON, Mass., Aug 09, 2010 (BUSINESS WIRE) -- Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quart...